



## Notice of Change of Interests of Substantial Securityholder

**Nyrada Inc (ASX: NYR),** a drug discovery and development company specialising in novel small molecule therapeutics to treat neurological and cardiovascular diseases advises, further to the Deed Poll dated 6 January 2020 issued by the Company in favour of ASX Limited in respect of the Initial Public Offering of its Chess Depositary Interests ("CDIs"), a Change of Interests of a Substantial Holder in relation to Nyrada. Details of the change in CDIs ("Relevant Interests") are as follows:

Name of Substantial Holder of Relevant Interests: Noxopharm Limited

Date of change in the interests of the Substantial Holder: 15 March 2024

# Previous and present voting power of Substantial Holder (through CHESS Depository Nominees Pty Ltd):

Previous notice		Present notice	
Number of CDIs	Voting power	Number of CDIs	Voting Power
33,373,245	21.39%	33,373,245	18.60%

#### **Present Relevant Interests:**

Holder of Relevant Interest	Registered Holdings of CDIs	Relevant Interest Number of CDIs	Voting Power
Noxopharm Limited	Noxopharm Limited	33,373,245	18.60%

- ENDS -



#### **About Nyrada Inc**

Nyrada is a drug discovery and development company specialising in novel small-molecule drugs to treat neurological and cardiovascular diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a drug to treat brain injury, specifically traumatic brain injury and stroke, and a cholesterol lowering drug. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

#### www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chair on behalf of the Board.

#### **Investor & Corporate Enquiries:**

Dimitri Burshtein T: 02 9498 3390

E: info@nyrada.com

### **Company Secretary:**

David Franks T: 02 8072 1400

E: David.Franks@automicgroup.com.au

#### **Media Enquiries:**

Catherine Strong Citadel-MAGNUS T: 02 8234 0111

E: <a href="mailto:cstrong@citadelmagnus.com">cstrong@citadelmagnus.com</a>

#### **Forward-Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.